Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors

Video

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

“The worry when we started was that we wouldn't see benefit, but we've seen it. So this really does 2 things. Number 1, it's an avenue for treatment for a significant subset of patients with advanced malignancy... But significantly, if this strategy is successful, this may open the world of T-cell therapies to the solid tumor world, in a way that we really have not had access to [in a large scale with] CAR-T or tumor-infiltrating lymphocyte therapies, due to the limitations of those modalities.”

Triumvira Immunologics’ TAC01-HER2, an investigational HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, is currently being evaluated in the phase 1/2 TACTIC-2 clinical trial(NCT04727151) for the treatment of patients with HER-2 positive solid tumors.

Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute, an investigator for the trial, recently presented data from TACTIC-2 at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, in Paris, France, and virtually.

In an interview with CGTLive, Schlechter discussed the key findings that have come out of the clinical trial so far, highlighting a patient’s objective response at 29 days as particularly impressive. He also went over what he sees as the potential advantages of TAC01-HER2 compared to the current standard of care for patients with HER2-positive solid tumors. Schlechter additionally discussed some challenges of the current trial and potential areas for further study. He concluded by recommending a re-examination of immunotherapy naming conventions in order to make the terminology more descriptive and educational for both the broader clinical community and patients.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.